CorMedix Inc. (NASDAQ:CRMD) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its stake in shares of CorMedix Inc. (NASDAQ:CRMD - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,378,191 shares of the company's stock after acquiring an additional 309,514 shares during the period. Vanguard Group Inc. owned about 5.57% of CorMedix worth $27,363,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. FMR LLC lifted its stake in shares of CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company's stock valued at $37,000 after purchasing an additional 1,625 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of CorMedix in the fourth quarter worth about $81,000. Aigen Investment Management LP purchased a new stake in shares of CorMedix during the 4th quarter worth about $94,000. Legato Capital Management LLC acquired a new stake in shares of CorMedix during the 4th quarter valued at about $97,000. Finally, BNP Paribas Financial Markets grew its position in shares of CorMedix by 130.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company's stock valued at $97,000 after acquiring an additional 6,761 shares during the period. 34.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on CRMD. D. Boral Capital reiterated a "buy" rating and set a $15.00 price target on shares of CorMedix in a research report on Tuesday, April 8th. Leerink Partnrs raised shares of CorMedix to a "strong-buy" rating in a research note on Friday, March 7th. Royal Bank of Canada restated an "outperform" rating and set a $12.00 price objective on shares of CorMedix in a research report on Wednesday, March 26th. StockNews.com upgraded shares of CorMedix from a "sell" rating to a "hold" rating in a research report on Tuesday, April 1st. Finally, Leerink Partners started coverage on shares of CorMedix in a research note on Friday, March 7th. They set an "outperform" rating and a $18.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $14.50.

CorMedix Price Performance

Shares of NASDAQ CRMD traded up $0.15 during mid-day trading on Friday, hitting $7.67. The company had a trading volume of 2,024,246 shares, compared to its average volume of 1,019,437. The company has a market capitalization of $499.95 million, a PE ratio of -9.47 and a beta of 1.57. The business's 50-day simple moving average is $8.92 and its 200 day simple moving average is $9.81. CorMedix Inc. has a 1-year low of $3.61 and a 1-year high of $13.85.

CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.17 by $0.05. The firm had revenue of $30.00 million during the quarter, compared to analysts' expectations of $27.46 million. CorMedix's revenue was up 29900.0% on a year-over-year basis. On average, analysts expect that CorMedix Inc. will post -0.32 EPS for the current year.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.